We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

600309:SSEWanhua Chemical Group Co. Ltd. Class A Analysis

Data as of 2026-09-17 - not real-time

CN¥70.78

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

The moving-average structure behind Wanhua Chemical Group Co., Ltd. is neutral at ¥70.78, with no clear ordering between short and long averages. Across the trailing 30 sessions it lost 4.9%. Momentum indicators put RSI at 37.6 (approaching oversold) with MACD reading bearish. Recent trading has carved out support near ¥69.10 and resistance around ¥79.28.
On valuation the read is undervalued — an earnings multiple of 13.9, absent a reliable peer benchmark. The average analyst target implies 38.5% above today's level. Revenue is growing at 36.4% on a 7.1% profit margin. The 2.91% dividend yield looks covered by current payout levels.
On a 1-10 scale the risk profile lands at 4 — moderate. With 30-day volatility of 30.1%, a beta of 0.12 and a maximum drawdown of 29.0%, position sizing matters here. The wider market backdrop reads extreme greed at 90 on the fear-greed composite.
This one splits by horizon — hold in the near term, buy further out, at 5/10 long-term conviction.

Top Market Events

Get the latest Wanhua Chemical Group Co., Ltd. 600309.SS stock news and headlines to help you in your trading and...On March 18, Wanhua Chemical Group Co., Ltd.Latest Wanhua Chemical Group Co Ltd 600309:SHH.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 1/10

Key Factors

  • Trading below the 200-day average of 78.01
  • MACD momentum is negative
  • Maximum drawdown of 29.0%

Medium Term

1–3 years
Neutral
Model confidence: 3/10

Key Factors

  • Trading below the 200-day average of 78.01
  • Analyst targets imply +38.5% versus the current price
  • MACD momentum is negative

Long Term

> 3 years
Positive
Model confidence: 5/10

Key Factors

  • Analyst targets imply +38.5% versus the current price
  • Revenue growth of +36.4%
  • P/E ratio of 13.9

Key Metrics & Analysis

Financial Health

Revenue Growth36.40%
Profit Margin7.11%
P/E Ratio13.9
ROE16.10%
ROA4.42%
Debt/Equity110.51
P/B Ratio2.0
Op. Cash FlowCN¥34.4B
Free Cash FlowCN¥5.9B

Technical Analysis

TrendNeutral
RSI37.6
SupportCN¥69.10
ResistanceCN¥79.28
MA 20CN¥75.49
MA 50CN¥74.05
MA 200CN¥78.01
MACDBearish
VolumeDecreasing
Fear & Greed Index89.8

Valuation

Fair ValueCN¥32.53
Target PriceCN¥98.04
Upside/Downside38.51%
GradeUndervalued
TypeBlend
Dividend Yield2.91%

Risk Assessment

Beta0.12
Volatility30.12%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskHigh
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.